Who We Are
CuraNova is a medical technology company specializing in AI-driven apheresis systems that redefine how clinicians separate, analyze, and collect blood components. Our multidisciplinary team of biomedical engineers, clinicians, and data scientists is united by one goal — advancing patient safety and efficiency in therapeutic cell and plasma exchange.
We design technology that adapts dynamically to each patient’s physiology, optimizing every collection for yield, quality, and comfort.
Where the Idea Began
CuraNova was founded by a small team of biomedical engineers and clinicians who saw the same problem repeated across hospitals — apheresis technology hadn’t evolved to meet the precision and efficiency modern therapies demand. Manual adjustments, inconsistent separations, and limited data feedback created unnecessary variability in patient outcomes. Our founders began experimenting with adaptive algorithms that could respond to live patient data in real time. What started as a research project in a Boston lab evolved into a vision: bring artificial intelligence to the core of blood technology
Securing the Capital to Scale
After early proof-of-concept success, CuraNova attracted attention from a consortium of medtech investors and clinical innovation funds. Backed by seed investment from MedVentures Capital and supported by grants from MassBio’s Early Innovation Program, the team transitioned from prototype to production. This funding enabled the development of the first fully integrated AI-driven apheresis system, complete with adaptive flow control and clinical data analytics.
Preparing for Deployment
Today, CuraNova is finalizing regulatory validation and preparing for commercial deployment across leading hospital systems and research centers. Pilot installations are underway to collect real-world data and refine workflow integration with existing clinical platforms. Our focus remains on reliability, compliance, and clinician training — ensuring that when CuraNova launches globally, every system delivers consistent, safe, and measurable improvements in patient outcomes.
Dr. Elena Voss
CEO
Dr. Elena Voss leads CuraNova with a vision to redefine therapeutic apheresis through intelligent automation. With over 20 years in medical device innovation and healthcare operations, she has guided multiple clinical technology startups from concept to commercialization. Dr. Voss combines strategic foresight with a commitment to patient-centered outcomes, driving CuraNova’s mission to integrate AI into next-generation blood separation systems that improve safety, efficiency, and clinical precision.
Chee Leong Chong
Lead Biomedical Engineer
Chee Leong Chong heads CuraNova’s engineering team, overseeing product design, system integration, and AI-driven optimization for apheresis devices. His background in biomedical systems and embedded machine learning enables the development of technology that adapts dynamically to each patient’s physiology. Chee’s engineering philosophy centers on reliability, scalability, and intuitive design ensuring CuraNova’s devices perform seamlessly in both research and clinical environments.
Danielle Reyes
Director of Business Development
Danielle drives CuraNova’s market growth and partnerships across hospitals, biotech organizations, and clinical research institutions. With a strong foundation in medical technology sales and strategic partnerships, her focuses on connecting CuraNova’s innovations to healthcare providers seeking efficiency and precision in blood therapies. Her leadership in business development reflects a deep understanding of both the clinical landscape and the commercial realities of medical device adoption.